Lurbinectedin is a novel anticancer agent that has shown promising results in clinical trials for the treatment of various types of cancer. According to a study published in Frontiers in Oncology [3], Lurbinectedin enhances the effectiveness of immunotherapy by increasing the expression of immune checkpoints and promoting the infiltration of immune cells into tumors.

Immune checkpoints are proteins that regulate the immune response, and their expression on tumor cells can prevent immune cells from attacking cancer cells. Lurbinectedin has been shown to increase the expression of immune checkpoints such as PD-L1 and CTLA-4, which can make tumor cells more vulnerable to immune attack [3].

In addition, Lurbinectedin can also increase the infiltration of immune cells into tumors, which can further enhance the immune response against cancer cells. A study published in the Journal of Clinical Oncology [2] found that Lurbinectedin increased the infiltration of T cells and natural killer cells into tumors, which resulted in a more robust immune response against cancer cells.

Overall, Lurbinectedin has the potential to enhance the effectiveness of immunotherapy by increasing the expression of immune checkpoints and promoting the infiltration of immune cells into tumors. This makes Lurbinectedin a promising candidate for combination therapy with immunotherapy for the treatment of cancer [1,2,3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.frontiersin.org/articles/10.3389/fonc.2023.1142081/full